论文部分内容阅读
Recent advances in genomic and proteomic technologies have stimulated a large number of molecular biomarker discovery studies of various diseases.To date,the number and the quality of the technical resources available for these biomarker studies and the rapid expansion of genomic and proteomic datasets are well recognized.However,the development of tailored statistical methods to address the challenges that have arisen in the field has lagged behind,dramatically reducing the pace,quality and precision of biomarker studies.